drugset / Trial / NCT02279966

Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder

NCT02279966

Phase 3 Completed 152 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy of acute treatment with 10 mg/day vortioxetine versus placebo on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning, attention) in working patients with major depressive disorder (MDD).

Timeline

Start
2014-10
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 20 mg Oral
Subject Vortioxetine Unknown 10 mg Oral